Lee's Pharmaceutical Holdings Ltd

Detailed Description

Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. The company focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. It operates in Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells self-developed and generic pharmaceutical products, such as Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; and fondaparinux sodium injection for deep vein thrombosis. The Licensed-In Products segment trades in licensed-in pharmaceutical products, such as Carnitene for the treatment of carnitine deficiency; Ferplex to treat iron deficiency anemia; Zanidip and Rasilez for hypertension; Aloxi and Sancuso for chemotherapy induced nausea and vomiting; and Gaslon N for gastric ulcer and gastritis. It also offers UNIDROX for urinary and respiratory tract infections; Levocarnitine oral solution to treat primary and secondary carnitine deficiency; Mictonorm for urinary incontinence; Trittico for insomnia/depression; Episil to treat oral mucositis pain; Dicoflor and VSL#3 for probiotics; Zingo for topical local analgesics; Omacor to treat for Omega-3-acid ethyl esters; Readyfusor for post-operative pain management; and Intrarosa for vulvovaginal atrophy. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.